Medical network - on February 21, 18, homebred the treatment of lung targeting drug (trade name: yi rui) product news conference was held in nanjing. It is understood that, compared to the treatment with the original research of qilu pharmaceutical production the treatment of the first domestic product equivalent, not only the high quality and cheaper prices. For further easing the burden on patients with poor, conference, qilu pharmaceutical to charities donated medicines, also used for free in patients with poor.
Expert introduction, lung cancer is one of the most common malignant tumor in the world, among them, non-small-cell lung cancer (NSCLC) accounts for about 80% of all lung cancer, about 75% of the patients has been found in the middle-late stage. Type and non-small cell lung cancer cells divide more slowly, diffusion transfer relatively late, the 5-year survival rate is low. For advanced non-small cell lung cancer, some patients can choose targeted drug treatment, the treatment is the preferred medicine. But as the original drug, the price is expensive, many patients.
In this background, as the country's main anti-tumor drugs and anti-infection drugs production enterprise, one of qilu pharmaceutical co., LTD., started in 2010, six years of research and development to produce biological equivalence with the original research article Yi Rui sand the treatment of the film, and was successfully listed in December 2016.
"Confirmed by comparing research, homebred can be consistent with the original medicine biological efficacy, clinical effect." Xiangya hospital, central south university expert professor guo-ping Yang, in the original drug, for reference preparations, qilu pharmaceutical co., LTD. (hainan) the treatment of the first domestic development, in the central south university xiangya hospital three stage Ⅰ clinical laboratory were human bioequivalence test, finally confirmed the biological equivalent.
According to introducing, qilu pharmaceutical, can be in consistent with the original drug quality under the premise of price reduction after about a third lower than the original medicine. Qilu pharmaceutical also joint Beijing rui kang au charitable foundation co-sponsored Iraq for charity activities: low-income patients in out-of-pocket medical 8 months and the accumulative total after 24 boxes can be given medicine; Low protect patients could receive up to eight months and accumulative total 24 box of trade-offs. The concrete issues can log on website http://yrk.bjhacf.org query.
In addition, in order to further improve the effect of lung cancer treatment, press conference, cancer experts, the Chinese academy of engineering miles d. jin-ming yu, Chinese academy of medical sciences tumor hospital professor kay and other relevant experts from all over the country, to form the lung cancer MDT (multidisciplinary treatment team) expert committee. According to introducing, MDT usually refers to by two or more of the experts in related disciplines and relatively fixed working group, according to a particular organ or system disease, through time, addressing the meeting, put forward the scientific and reasonable mode of clinical treatment.
Member of jin-ming yu said, "lung cancer MDT expert committee", through joint leading experts in the field of national lung cancer, for the treatment of lung cancer and progressive ideas, with the strength of multidisciplinary, seek the welfare of patients, and at the same time in order to further strengthen the interdisciplinary communication, promote the cooperation between specialized subject, multidisciplinary sharing.
|
